Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>G Sachs Upgrades JD HEALTH to Buy, Downgrades ALI HEALTH to Neutral
Recommend 29 Positive 39 Negative 16 |
||||
|
||||
|
Goldman Sachs released a research report, considering that the online healthcare industry is benefiting from increased pharma penetration and policy support. It revisited its stock preference and upgraded JD HEALTH (06618.HK) to Buy from Neutral, and downgraded ALI HEALTH (00241.HK) to Neutral from Buy, reflecting the fact that JD HEALTH is better positioned than ALI HEALTH on the ride of prescription and OTC drugs, as well as online/offline integration. The broker raised its target price on JD HEALTH from $28 to $33.5 accordingly. Goldman Sachs also raised its revenue and net profit forecasts on JD HEALTH for 2025 by 1% and 2026 by 2%. As for ALI HEALTH, its target price was trimmed to $4 from $4.4, and its revenue forecasts for 2024-26 were cut by 5%/ 7%/ 6%, while its net profit forecasts for 2025-26 were lowered by 7%/ 9%. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
